Track Oncolytics Biotech Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Oncolytics Biotech Inc. ONCY · Stock Open Oncolytics Biotech Inc. in new tab

0.3700 USD
EPS
-0.35
P/B
-7.55
ROE
-769.06
Beta
1.24
Target Price
4.42 USD
Loading chart...
Key Metrics
Earnings dateFeb. 26, 2027
EPS-0.35
Book Value-0.05
Price to Book-7.55
Debt/Equity726.09
% Insiders1.662%
Estimates
Forward P/E-1.86
Forward EPS-0.20
Target Mean Price4.42

DCF valuation

Model fair value for Oncolytics Biotech Inc. (ONCY)
Result
Sign in to run the valuation for ONCY.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
5 analysts · consensus Buy · mean target 4.42 USD (low 2.84, high 5.84) · as of 14 Nov 2026
Low 2.84
Mean 4.42
High 5.84
Price 0.3700
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Oncolytics Biotech Inc. Logo Oncolytics Biotech Inc. Analysis (ONCY)

Canada Health Care Official Website Stock

Is Oncolytics Biotech Inc. a good investment? Oncolytics Biotech Inc. (ONCY) is currently trading at 0.3700 USD. Market analysts have a consensus price target of 4.42 USD. This suggests a potential upside from current levels.

Earnings Schedule: Oncolytics Biotech Inc. is expected to release its next earnings report on Feb. 26, 2027. The market consensus estimate for Forward EPS is -0.20.

Investor FAQ

Does Oncolytics Biotech Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Oncolytics Biotech Inc.?

Oncolytics Biotech Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 26, 2027. The company currently has a trailing EPS of -0.35.

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Exchange Ticker
NMS (United States) ONCY
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
May 25, 2018 0.11
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion